Pentapiperide is an anticholinergic drug with antisecretory and antimotility activity on the upper gastrointestinal tract, which was used as adjunctive therapy for relieving the symptoms of peptic ulcer. pentapiperide methylsulfate) has approximately the same in vitro antispasmodic activity as atropine. In vivo, however, the quaternary ammonium compounds such as pentapiperide methylsulfate are less readily absorbed from the gastrointestinal tract than are the tertiary amines such as atropine. Pentapiperide methylsulfate is contraindicated in patients with glaucoma or a predisposition to glaucoma, in patients with pyloric obstruction or stenosis, gastric retention, known or suspected obstructive disease of the gastrointestinal tract, and urinary bladder neck obstruction. It is also contraindicated in prostatic hypertrophy, stenosing peptic ulcer, megaesophagus, organic cardiospasm, and in patients with a hypersensitivity to the drug. Xerostomia was the most frequently encountered complaint. In decreasing order of frequency, visual blurring, difficult micturition, constipation, and nausea were reported.